266 related articles for article (PubMed ID: 3771793)
1. Familial apolipoprotein E deficiency.
Schaefer EJ; Gregg RE; Ghiselli G; Forte TM; Ordovas JM; Zech LA; Brewer HB
J Clin Invest; 1986 Nov; 78(5):1206-19. PubMed ID: 3771793
[TBL] [Abstract][Full Text] [Related]
2. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
de Knijff P; van den Maagdenberg AM; Boomsma DI; Stalenhoef AF; Smelt AH; Kastelein JJ; Marais AD; Frants RR; Havekes LM
J Clin Invest; 1994 Sep; 94(3):1252-62. PubMed ID: 8083367
[TBL] [Abstract][Full Text] [Related]
3. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.
de Knijff P; van den Maagdenberg AM; Stalenhoef AF; Leuven JA; Demacker PN; Kuyt LP; Frants RR; Havekes LM
J Clin Invest; 1991 Aug; 88(2):643-55. PubMed ID: 1864973
[TBL] [Abstract][Full Text] [Related]
4. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
[TBL] [Abstract][Full Text] [Related]
5. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
Smelt AH
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
[TBL] [Abstract][Full Text] [Related]
6. Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia.
Feussner G; Dobmeyer J; Nissen H; Hansen TS
Am J Med Genet; 1996 Oct; 65(2):149-54. PubMed ID: 8911609
[TBL] [Abstract][Full Text] [Related]
7. High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene.
Lackner KJ; Dieplinger H; Nowicka G; Schmitz G
J Clin Invest; 1993 Nov; 92(5):2262-73. PubMed ID: 7693760
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
9. Characterization of very low density lipoproteins and intermediate density lipoproteins of normo- and hyperlipidemic apolipoprotein E-2 homozygotes.
Schmitz G; Assmann G; Augustin J; Dirkes-Kersting A; BrennhaĆ¼sen B; Karoff C
J Lipid Res; 1985 Mar; 26(3):316-26. PubMed ID: 3989390
[TBL] [Abstract][Full Text] [Related]
10. Catabolism of very-low-density lipoproteins in subjects with broad beta disease: comparison with endogenous hypertriglyceridemia.
Kushwaha RS; Chait A; Hazzard WR
J Lab Clin Med; 1982 Jan; 99(1):15-24. PubMed ID: 6948063
[TBL] [Abstract][Full Text] [Related]
11. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.
Ikewaki K; Nishiwaki M; Sakamoto T; Ishikawa T; Fairwell T; Zech LA; Nagano M; Nakamura H; Brewer HB; Rader DJ
J Clin Invest; 1995 Sep; 96(3):1573-81. PubMed ID: 7657828
[TBL] [Abstract][Full Text] [Related]
12. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.
de Knijff P; van den Maagdenberg AM; Frants RR; Havekes LM
Hum Mutat; 1994; 4(3):178-94. PubMed ID: 7833947
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
Smelt AH; de Beer F
Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
[TBL] [Abstract][Full Text] [Related]
14. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
[TBL] [Abstract][Full Text] [Related]
15. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
[TBL] [Abstract][Full Text] [Related]
16. Non-HDL-cholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia.
Murase T; Okubo M; Takeuchi I
J Clin Lipidol; 2010; 4(2):99-104. PubMed ID: 21122636
[TBL] [Abstract][Full Text] [Related]
17. ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice.
Hinsdale ME; Sullivan PM; Mezdour H; Maeda N
J Lipid Res; 2002 Sep; 43(9):1520-8. PubMed ID: 12235184
[TBL] [Abstract][Full Text] [Related]
18. A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency.
Mabuchi H; Itoh H; Takeda M; Kajinami K; Wakasugi T; Koizumi J; Takeda R; Asagami C
Metabolism; 1989 Feb; 38(2):115-9. PubMed ID: 2492364
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia.
Gregg RE; Ghiselli G; Brewer HB
J Clin Endocrinol Metab; 1983 Nov; 57(5):969-74. PubMed ID: 6578216
[TBL] [Abstract][Full Text] [Related]
20. Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins.
Mulder M; van der Boom H; de Knijff P; Braam C; van den Maagdenberg A; Leuven JA; Havekes LM
Atherosclerosis; 1994 Aug; 108(2):183-92. PubMed ID: 7980718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]